StockData

Evotec vs Schrodinger

EVO and SDGR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How EVO and SDGR compare

Schrodinger grew revenue faster over the last twelve months (4.8% versus −1.1% for Evotec).

Schrodinger scores higher on the StockData Score (12 against 4 for Evotec), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricEVOSDGR
Size and price
Market cap–$2.4B
Share price$1.69$31.52
Change, 1 year−43.5%72.3%
Change, 5 years−92.9%−22.7%
Beta (5Y)1.261.85
Employees4,553850
StockData Score
Total score412 (better)
Valuation score00
Growth score13 (better)
Performance score03 (better)
Health score36 (better)
Dividend score00
Valuation
P/S–8.8×
P/B–7.8×
FCF yield–−5.0%
Fair value–$17.66
Margin of safety–−78.5%
Growth
Revenue growth (TTM)−1.1%4.8% (better)
Revenue growth, 5Y average9.5%18.8% (better)
Profitability
Gross margin14.5%58.5% (better)
Operating margin−7.1% (better)−49.6%
Net margin–−22.0%
FCF margin−10.4% (better)−43.4%
Return on equity–−19.0%
Return on invested capital−7.7%–
Financial health
Debt / equity0.10 (better)0.00
Net debt / EBITDA−7.79–
Current ratio2.072.75 (better)
Altman Z-score–3.20
Piotroski F-score–5
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions1.8%86.5%
Held by insiders17.1%3.2%
Insider net buying, 12 months–−$3.4M
Superinvestors holding–1
Short interest, % of float–13.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.